Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Understanding secondary immunodeficiency management in patients with hematological malignancies

Adil Adatia, Meritxell Pons-Espinal, Elisabeth Calderón-Gómez et al. Nov 03, 2025 pp. 6182-6182 10.1182/blood-2025-6182

Abstract Background: Secondary antibody deficiency (SAbD) is a prevalent immune disorder characterized by impaired specific antibody product...

Improving outcomes with nivolumab consolidation among older patients (≥65) with previously untreated primary CNS lymphoma

Steven Park, Lakshmi Nayak, Danielle Boselli et al. Nov 03, 2025 pp. 1968-1968 10.1182/blood-2025-1968

Abstract Introduction: Autologous stem cell transplant (ASCT) is widely accepted as the standard consolidation therapy for primary CNS lymph...

Integrating palliative care for adolescents and young adults with hematologic malignancies: Insights from a dedicated french unit.

Agathe Picard, Victoria Hadida, Matthieu Jestin et al. Nov 03, 2025 pp. 4618-4618 10.1182/blood-2025-4618

Abstract Context. The outcome of adolescents and young adults (AYA) aged 15 to 25 with cancer has improved, with five-year survival rates no...

Development of a machine learning model to predict overall survival in patients with peripheral T-cell lymphoma in a minority enriched population

Kimberly Seymour, Nicholas Li, Emma Cordover et al. Nov 03, 2025 pp. 2568-2568 10.1182/blood-2025-2568

Abstract Introduction: Peripheral T-cell lymphomas (PTCL) are a group of heterogeneous lymphomas that arise from mature T-cells and comprise...

A triple threat to diagnostic safety in CTPA: Diagnostic uncertainty, sspe, and reporting discrepancies

Abdulrahman Al Raizah, Aimn W Abdujawad, Mohammed Snnallah et al. Nov 03, 2025 pp. 2605-2605 10.1182/blood-2025-2605

Abstract Background: CT pulmonary angiography (CTPA) is the gold standard for diagnosing pulmonary embolism (PE), yet inconsistencies in rep...

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis

Moazzam Shahzad, Farooq Ashraf, Sayyam Razzaq et al. Nov 03, 2025 pp. 2689-2689 10.1182/blood-2025-2689

Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy driven by complement...

Imputing causality from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria

Hiroki Mizumaki, Shouguo Gao, Zhijie Wu et al. Nov 03, 2025 pp. 4980-4980 10.1182/blood-2025-4980

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare life-threatening acquired disease, clinically manifest as intravascu...

Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient-derived xenograft mouse models

Chan Yang, Qinglong Guo, Hui Hui et al. Nov 03, 2025 pp. 3277-3277 10.1182/blood-2025-3277

Abstract Introduction: Enhancer of Zeste 2 (EZH2) is the enzymatic subunit of Polycomb Repressive Complex 2 (PRC2) that is highly upregulated...

Mechanisms of immune escape and altered tissue homing in leukemia cutis

Livius Penter, Alexandria Maurer, Nicoletta Cieri et al. Nov 03, 2025 pp. 2483-2483 10.1182/blood-2025-2483

Abstract Extramedullary acute myeloid leukemia (eAML) relapse is frequent after allogeneic hematopoietic cell transplantation (HCT), suggest...

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Kelsey Baron, Charlotte Wagner, Lindsey Fitzgerald et al. Nov 03, 2025 pp. 4485-4485 10.1182/blood-2025-4485

Abstract Introduction: Cytokine release syndrome (CRS) is a common adverse event associated with the bispecific antibody (BsAb), epcoritamab...

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Yuan Jian, Long Chang, Shi Minxia et al. Nov 03, 2025 pp. 5818-5818 10.1182/blood-2025-5818

Abstract BACKGROUND Renal impairment (RI) affects 20-40% of newly diagnosed multiple myeloma (NDMM) patients and independently predicts adve...

Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study

Juan Wang, Furun An, Zhouning Lin et al. Nov 03, 2025 pp. 6854-6854 10.1182/blood-2025-6854

Abstract Purpose: CD19 chimeric antigen receptor T-cell (CAR-T) therapy demonstrates remarkable efficacy in patients with B-Cell Acute Lymph...

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma

Amy Huang, Nicole Sequeira, Anthony Zhang et al. Nov 03, 2025 pp. 4567-4567 10.1182/blood-2025-4567

Abstract Introduction Skeletal-related events (SREs) in multiple myeloma (MM) contribute to significant morbidity. Bone-modifying agents (BM...

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada et al. Nov 03, 2025 pp. 2301-2301 10.1182/blood-2025-2301

Abstract Background: The two commercially available CART constructs targeting BCMA (Ide-cel and Cilta-cel) were approved initially for patie...

The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells

Michael Wang, Yang Liu, Qingsong Cai et al. Nov 03, 2025 pp. 330-330 10.1182/blood-2025-330

Abstract Background Drug-tolerant persister (DTP) cells are increasingly recognized as a key contributor to therapy resistance in cancer pat...

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

khaire Niranjan, Susan Wu, Nitin Jain et al. Nov 03, 2025 pp. 3326-3326 10.1182/blood-2025-3326

Abstract Background: Outcomes of patients (pts) with B-cell acute lymphoblastic leukemia (B-ALL) have improved significantly with the introdu...

Clinical features and outcomes of myelofibrosis patients with MPL mutations

Yu-Han Chen, Shruti Gajjar, Victor You et al. Nov 03, 2025 pp. 5601-5601 10.1182/blood-2025-5601

Abstract Background Myelofibrosis (MF) is a type of myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic...

Enhanced clinical and systemic response with combination radiation therapy and topical imiquimod in mycosis fungoides: A pilot study

Katherine De Jong, Eleanor Ostroff, JoJo Holm et al. Nov 03, 2025 pp. 3655-3655 10.1182/blood-2025-3655

Abstract Introduction: Mycosis fungoides (MF), the most prevalent type of cutaneous T-cell lymphoma (CTCL), presents significant therapeutic...

Unravelling the biological and clinical features of childhood B-cell precursor acute lymphoblastic leukemia with monosomy 7

Agata Pastorczak, Kinga Ostrowska, Kamila Wypyszczak et al. Nov 03, 2025 pp. 5145-5145 10.1182/blood-2025-5145

Abstract Monosomy of chromosome 7 is a common cytogenetic aberration predicting prognosis in myeloid malignancies and promoting transformati...

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue et al. Nov 03, 2025 pp. 4494-4494 10.1182/blood-2025-4494

Abstract Background Primary central nervous system lymphoma (PCNSL) is a rare but aggressive non-Hodgkin lymphoma with limited prospective d...

Age-associated non-mutational resistance in acute myeloid leukemia is driven by DNA damage-induced transcriptional heterogeneity

Jordon Burton, Kristin Pladna, Lance Miller et al. Nov 03, 2025 pp. 639-639 10.1182/blood-2025-639

Abstract Older patients with acute myeloid leukemia (AML) have significantly worse response rates and overall survival compared to younger p...

Meteorological impact on ventricular arrhythmias in sickle cell disease

Thibaut Moulin, Thomas d'Humieres, Laurent Savale et al. Nov 03, 2025 pp. 2965-2965 10.1182/blood-2025-2965

Abstract Background: Patients with sickle cell disease (SCD) are known to have a heightened burden of ventricular ectopy, yet the contributi...

In Vivo generation of anti-CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases

Eli Pasackow, Camille Khairallah, Joshua Ferrell et al. Nov 03, 2025 pp. 4106-4106 10.1182/blood-2025-4106

Abstract Emerging clinical data demonstrate the transformative potential of B cell-depleting CAR-T therapies for patients with autoimmune di...

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Qingqing Cai, Yi Cao, Danling Dai et al. Nov 03, 2025 pp. 3527-3527 10.1182/blood-2025-3527

Abstract Background :Natural killer T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma (NHL) characterized by rapid progressio...

Warm autoimmune hemolytic anemia following epstein-barr virus reactivation: An uncommon clinical association

Felix Lee, Kurush Setna, Abhishek Singh et al. Nov 03, 2025 pp. 6448-6448 10.1182/blood-2025-6448

Abstract Introduction: Autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the immune system's destruction of red blood...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page